Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABRA1 | P14867 | 1/20 | 0.52 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.52 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.48 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.41 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.41 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.41 |
| ▸ | ALOX15 | P16050 | 4/20 | 0.41 |
| ▸ | HPGD | P15428 | 2/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.41 |
| ▸ | LMNA | P02545 | 3/20 | 0.40 |
| ▸ | TYR | P14679 | 2/20 | 0.40 |
| ▸ | CA2 | P00918 | 2/20 | 0.39 |
| ▸ | CA1 | P00915 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.37 |
| ▸ | POLB | P06746 | 2/20 | 0.37 |
| ▸ | MAPT | P10636 | 2/20 | 0.37 |
| ▸ | RECQL | P46063 | 2/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23079300 | 0.90 | ALDH1A1 (0.48) | GABRA1GABRB2CYP2C19CYP1A2HIF1A | |
| SCHEMBL26607076 | 0.88 | GABRA1 (0.46) | GABRA1GABRB2CYP2C19CYP1A2HIF1A | |
| SCHEMBL544725 | 0.84 | ALOX15 (0.52) | GABRA1GABRB2CYP2C19HIF1AALDH1A1 | |
| SCHEMBL4463634 | 0.84 | ALOX15 (0.36) | GABRA1GABRB2CYP2C19HIF1AALDH1A1 | |
| SCHEMBL13176669 | 0.80 | ALOX15 (0.33) | GABRA1GABRB2CYP2C19HIF1AALDH1A1 | |
| SCHEMBL24197756 | 0.80 | IDH1 (0.38) | GABRA1GABRB2CYP2C19HIF1AALDH1A1 | |
| SCHEMBL31152503 | 0.80 | ERN1 (0.58) | ALDH1A1LMNASMN1; SMN2MEN1KMT2A | |
| SCHEMBL31152505 | 0.80 | ERN1 (0.58) | ALDH1A1LMNASMN1; SMN2MEN1KMT2A | |
| SCHEMBL18176659 | 0.78 | ALDH1A1 (0.46) | GABRA1GABRB2CYP2C19CYP1A2HIF1A | |
| SCHEMBL7847209 | 0.78 | GABRA1 (0.43) | GABRA1GABRB2CYP2C19ALDH1A1ALOX15 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 43 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240239764-A1 | SUBSTITUTED AMINOBENZYL HETEROARYL COMPOUNDS AS EGFR AND/OR PI3K INHIBITORS | THE REGENTS OF THE UNIVERSITY OF MICHIGAN | 2024-07-18 | — | — | US | disclosed |
| US-11840521-B2 | Modulators of Mas-related G-protein receptor X4 and related products and methods | ESCIENT PHARMACEUTICALS, INC. (US) | 2023-12-12 | — | — | US | disclosed |
| US-11840521-B2 | Modulators of Mas-related G-protein receptor X4 and related products and methods | ESCIENT PHARMACEUTICALS, INC. (US) | 2023-12-12 | — | — | US | disclosed |
| US-20230226214-A1 | BIFUNCTIONAL BRIDGING COMPOSITIONS FOR VIRAL TRANSDUCTION | LYCIA THERAPEUTICS, INC. | 2023-07-20 | — | — | US | disclosed |
| US-20230226214-A1 | BIFUNCTIONAL BRIDGING COMPOSITIONS FOR VIRAL TRANSDUCTION | LYCIA THERAPEUTICS, INC. | 2023-07-20 | — | — | US | disclosed |
| US-11673876-B2 | Substituted aminobenzyl heteroaryl compounds as EGFR and/or PI3K inhibitors | MEKANISTIC THERAPEUTICS LLC (US) | 2023-06-13 | — | — | US | disclosed |
| US-11673876-B2 | Substituted aminobenzyl heteroaryl compounds as EGFR and/or PI3K inhibitors | MEKANISTIC THERAPEUTICS LLC (US) | 2023-06-13 | — | — | US | disclosed |
| US-20230159474-A1 | MODULATORS OF MAS-RELATED G-PROTEIN RECEPTOR X4 AND RELATED PRODUCTS AND METHODS | INCYTE CORPORATION | 2023-05-25 | — | — | US | disclosed |
| US-20230159474-A1 | MODULATORS OF MAS-RELATED G-PROTEIN RECEPTOR X4 AND RELATED PRODUCTS AND METHODS | INCYTE CORPORATION | 2023-05-25 | — | — | US | disclosed |
| US-11643399-B2 | Modulators of mas-related G-protein receptor X4 and related products and methods | ESCIENT PHARMACEUTICALS, INC. (US) | 2023-05-09 | — | — | US | disclosed |
| US-20120071412-A1 | METHODS OF USING MACROCYCLIC AGONISTS OF THE GHRELIN RECEPTOR FOR TREATMENT OF GASTROINTESTINAL MOTILITY DISORDERS | FRASER GRAEME L (BE) | 2012-03-22 | — | — | US | disclosed |
| US-8088733-B2 | Methods of using macrocyclic agonists of the ghrelin receptor for treatment of gastrointestinal motility disorders | TRANZYME PHARMA INC. (CA) | 2012-01-03 | — | — | US | disclosed |
| US-8088733-B2 | Methods of using macrocyclic agonists of the ghrelin receptor for treatment of gastrointestinal motility disorders | TRANZYME PHARMA INC. (CA) | 2012-01-03 | — | — | US | disclosed |
| US-20100292273-A1 | Cannabinoid Receptor Modulators | 7TM PHARMA A/S (DK) | 2010-11-18 | — | — | US | disclosed |
| US-20100093720-A1 | MACROCYCLIC ANTAGONISTS OF THE MOTILIN RECEPTOR FOR TREATMENT OF GASTROINTESTINAL DYSMOTILITY DISORDERS | MALLINCKRODT PHARMACEUTICALS IRELAND LIMITED (IE) | 2010-04-15 | — | — | US | disclosed |
| US-20100093720-A1 | MACROCYCLIC ANTAGONISTS OF THE MOTILIN RECEPTOR FOR TREATMENT OF GASTROINTESTINAL DYSMOTILITY DISORDERS | MALLINCKRODT PHARMACEUTICALS IRELAND LIMITED (IE) | 2010-04-15 | — | — | US | disclosed |
| US-20080287371-A1 | MACROCYCLIC ANTAGONISTS OF THE MOTILIN RECEPTOR FOR MODULATION OF THE MIGRATING MOTOR COMPLEX | TRANZYME PHARMA INC. | 2008-11-20 | — | — | US | disclosed |
| US-20080287371-A1 | MACROCYCLIC ANTAGONISTS OF THE MOTILIN RECEPTOR FOR MODULATION OF THE MIGRATING MOTOR COMPLEX | TRANZYME PHARMA INC. | 2008-11-20 | — | — | US | disclosed |
| US-20080051383-A1 | METHODS OF USING MACROCYCLIC AGONISTS OF THE GHRELIN RECEPTOR FOR TREATMENT OF GASTROINTESTINAL MOTILITY DISORDERS | TRANZYME PHARMA INC. | 2008-02-28 | — | — | US | disclosed |
| WO-2007120012-A1 | NOVEL COMPOUNDS, ISOMER THEREOF, OR PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF AS VANILLOID RECEPTOR ANTAGONIST; AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME | AMOREPACIFIC CORPORATION (KR) | 2007-10-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11840521-B2 | Modulators of Mas-related G-protein receptor X4 and related products and methods | MRGPRX4, MRGPRX1, MRGPRX2 | GABRA1 309/4885GABRB2 634/4885CYP2C19 1670/4885 |
| US-20080051383-A1 | METHODS OF USING MACROCYCLIC AGONISTS OF THE GHRELIN RECEPTOR FOR TREATMENT OF GASTROINTESTINAL MOTILITY DISORDERS | GHSR, GIPR, GHRHR | GABRA1 205/4885GABRB2 348/4885CYP2C19 1211/4885 |
| US-20100292273-A1 | Cannabinoid Receptor Modulators | CNR1, CNR2, CBR1 | GABRA1 164/4885GABRB2 385/4885CYP2C19 194/4885 |
| US-20100093720-A1 | MACROCYCLIC ANTAGONISTS OF THE MOTILIN RECEPTOR FOR TREATMENT OF GASTROINTESTINAL DYSMOTILITY DISORDERS | MLNR, GIPR, GPR39 | GABRA1 2311/4885GABRB2 1972/4885CYP2C19 898/4885 |
| US-20240239764-A1 | SUBSTITUTED AMINOBENZYL HETEROARYL COMPOUNDS AS EGFR AND/OR PI3K INHIBITORS | EGFR, ERBB2, ERBB3 | GABRA1 2573/4885GABRB2 2066/4885CYP2C19 1701/4885 |
| US-11643399-B2 | Modulators of mas-related G-protein receptor X4 and related products and methods | MRGPRX4, MRGPRX1, MRGPRX2 | GABRA1 309/4885GABRB2 634/4885CYP2C19 1670/4885 |
| US-11673876-B2 | Substituted aminobenzyl heteroaryl compounds as EGFR and/or PI3K inhibitors | EGFR, ERBB2, ERBB3 | GABRA1 2573/4885GABRB2 2066/4885CYP2C19 1701/4885 |
| US-20230226214-A1 | BIFUNCTIONAL BRIDGING COMPOSITIONS FOR VIRAL TRANSDUCTION | HAVCR2, FCGR3B, FCGR2A | GABRA1 2022/4885GABRB2 2238/4885CYP2C19 4862/4885 |
| US-20230159474-A1 | MODULATORS OF MAS-RELATED G-PROTEIN RECEPTOR X4 AND RELATED PRODUCTS AND METHODS | MRGPRX4, MRGPRX1, MRGPRX2 | GABRA1 309/4885GABRB2 634/4885CYP2C19 1670/4885 |
| US-20080287371-A1 | MACROCYCLIC ANTAGONISTS OF THE MOTILIN RECEPTOR FOR MODULATION OF THE MIGRATING MOTOR COMPLEX | MLNR, CCKAR, CCKBR | GABRA1 1787/4885GABRB2 1474/4885CYP2C19 474/4885 |
| US-20120071412-A1 | METHODS OF USING MACROCYCLIC AGONISTS OF THE GHRELIN RECEPTOR FOR TREATMENT OF GASTROINTESTINAL MOTILITY DISORDERS | GHSR, GIPR, GHRHR | GABRA1 205/4885GABRB2 348/4885CYP2C19 1211/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.